IntraMed - Artículos - Guias para el Tratamiento Farmacológico de la Insuficiencia Cardiaca
Insuficiencia cardíaca crónica | 02 OCT 02
Guias para el Tratamiento Farmacológico de la Insuficiencia Cardiaca
El tratamiento farmacológico debe ser orientado a obtener alivio sintomático, mantener estabilidad clínica y mejorar la sobrevida.
(1)
Autor: Dr. Hugo Grancelli 
Bibliografía

The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N  Engl J Med 1987; 316: 1429-1435.

The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.

Garg R, Yusuf S; for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450-56..

The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-691.

Pitt B, Poole-Wilson P, Segal R y col. Effect of losartan compared with captopril on mortality in patients with   symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-87.

Cohn J, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75.    

Pitt B, Zannad F,Remme WJ, Cody R, Castaigne A. Perez A, Palensky J, Wittes J, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.

Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, for the US  Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-355

CIBIS II Investigators and Committes. The Cardiac Insufficiency Bisoprolol Study (CIBIS II): a randomized trial .Lancet 1999 ;353: 9-13

  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) MERIT- HF Investigators. Lancet 1999;353(9169):2001-7

 Packer M, Coats A, Fowler M, y col. The effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-58

  The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction): the CAPRICORN trial. Lancet 2001; 357: 1385-90

  Exner D, Dries D, Waclawiw M, Shelton B, Domanski M. Beta- adrenergic blocking agent   use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction. J Am Coll Cardiol 1999; 33: 916-923.  

  Doughty R, whalley G, Gamble G, MacMahon S, SharpeN. Left ventricular remodeling with Carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1997; 29: 1060-1066.

 Krum H,Sackner-Bernstein JD, Goldsmith RL Kukin ML, Schwartz B, Packer M. Double-blind, placebo-controlled  trial study of the long term efficacy of carvedilol in patients with  severe chronic heart failure . Circulation 1995;92:1499-1506.

 Packer M, Gheorghiade M, Young J, y col. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin converting enzyme inhibitors. N Engl J Med 1993; 329:1-7

 The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533.

Doval H, Nul D, Grancelli H, y col., for the Grupo de Estudio de la Sobrevida en la Insuficencia Cardíaca en Argentina (GESICA) Investigators.  Randomised trial of low-dose amiodarone in sever congestive heart failure.  Lancet 1994; 344: 493-498.

.Nul D, Doval H, Grancelli H, y col., on Behalf the GESICA-GEMA Investigators. Heart Rate is a Marker of Amiodarone Mortality Reduction in Severe Heart Failure.J Am Coll Cardiol 1997;29:1199-205.

 Baker D, Wright R.  Management of heart failure. IV-anticoagulation for patients with heart failure due to ventricular systolic dysfunction. JAMA 1994; 272:1614-8.

Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154: 1449.

Philbin E. Comprehensive multidisciplinary programs for the management of patients with congestive heart failure. J Gen Intern Med 1999; 14: 130-135.

(1)

Comentarios

Usted debe estar registrado para expresar su opinión. Si ya es usuario de IntraMed o desea registrase como nuevo usuario, ingrese aquí
Los más...
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2014